Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd (OXYGENTAPH) is a micro-cap Healthcare company valued at ₹172 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Oxygenta Pharmaceutical Ltd last traded at ₹46.6, modestly down 0.85% on the day.

Recent developments

On 2026-09-30, promoter holding was reported at 56.54%, consistent with prior periods. The company reported a net loss of ₹18 crore in its latest financial year ending 2026-03-31, reflecting a widening loss compared to the prior year.

Financial performance

The company's revenue grew 3.4% annually, but net profit worsened as a loss widened from ₹10 crore to ₹18 crore. The latest quarter saw revenue surge 144.5% year-over-year to ₹37 crore, while the net loss narrowed from ₹6 crore to ₹2 crore.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at -4.66 times book value.

Things to watch

The company reported a net loss of ₹18 crore in its latest financial year, with the net profit margin declining to -15.6% from -9.4% the prior year. The return on capital employed is negative at -26.0%, indicating poor efficiency in using capital.

Where it stands

The company's revenue grew 3.4% annually, but net profit deteriorated as a loss widened from ₹10 crore to ₹18 crore. The latest quarter saw a significant revenue increase of 144.5% year-over-year, though the net loss narrowed to ₹2 crore.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.